@article{fdi:010084326,
  title = {{M}icrobiome and metabolome features of the cardiometabolic disease spectrum},
  author = {{F}romentin, {S}. and {F}orslund, {S}. {K}. and {C}hechi, {K}. and {A}ron-{W}isnewsky, {J}. and {C}hakaroun, {R}. and {N}ielsen, {T}. and {T}remaroli, {V}. and {J}i, {B}. {Y}. and {P}rifti, {E}di and {M}yridakis, {A}. and {C}hilloux, {J}. and {A}ndrikopoulos, {P}. and {F}an, {Y}. and {O}lanipekun, {M}. {T}. and {A}lves, {R}. and {A}diouch, {S}. and {B}ar, {N}. and {T}almor-{B}arkan, {Y}. and {B}elda, {E}. and {C}aesar, {R}. and {C}oelho, {L}. {P}. and {F}alony, {G}. and {F}ellahi, {S}. and {G}alan, {P}. and {G}alleron, {N}. and {H}elft, {G}. and {H}oyles, {L}. and {I}snard, {R}. and {L}e {C}hatelier, {E}. and {J}ulienne, {H}. and {O}lsson, {L}. and {P}edersen, {H}. {K}. and {P}ons, {N}. and {Q}uinquis, {B}. and {R}ouault, {C}. and {R}oume, {H}. and {S}alem, {J}. {E}. and {S}chmidt, {T}. {S}. {B}. and {V}ieira-{S}ilva, {S}. and {L}i, {P}. {S}. and {Z}immermann-{K}ogadeeva, {M}. and {L}ewinter, {C}. and {S}ondertoft, {N}. {B}. and {H}ansen, {T}. {H}. and {G}auguier, {D}. and {G}otze, {J}. {P}. and {K}ober, {L}. and {K}ornowski, {R}. and {V}estergaard, {H}. and {H}ansen, {T}. and {Z}ucker, {J}ean-{D}aniel and {H}ercberg, {S}. and {L}etunic, {I}. and {B}ackhed, {F}. and {O}ppert, {J}. {M}. and {N}ielsen, {J}. and {R}aes, {J}. and {B}ork, {P}. and {S}tumvoll, {M}. and {S}egal, {E}. and {C}lement, {K}. and {D}umas, {M}. {E}. and {E}hrlich, {S}. {D}. and {P}edersen, {O}.},
  editor = {},
  language = {{ENG}},
  abstract = {{B}y studying individuals along a spectrum of cardiometabolic disease and adjusting for effects of lifestyle and medication, this investigation identifies alterations of the metabolome and microbiome from dysmetabolic conditions, such as obesity and type 2 diabetes, to ischemic heart disease. {P}revious microbiome and metabolome analyses exploring non-communicable diseases have paid scant attention to major confounders of study outcomes, such as common, pre-morbid and co-morbid conditions, or polypharmacy. {H}ere, in the context of ischemic heart disease ({IHD}), we used a study design that recapitulates disease initiation, escalation and response to treatment over time, mirroring a longitudinal study that would otherwise be difficult to perform given the protracted nature of {IHD} pathogenesis. {W}e recruited 1,241 middle-aged {E}uropeans, including healthy individuals, individuals with dysmetabolic morbidities (obesity and type 2 diabetes) but lacking overt {IHD} diagnosis and individuals with {IHD} at three distinct clinical stages-acute coronary syndrome, chronic {IHD} and {IHD} with heart failure-and characterized their phenome, gut metagenome and serum and urine metabolome. {W}e found that about 75% of microbiome and metabolome features that distinguish individuals with {IHD} from healthy individuals after adjustment for effects of medication and lifestyle are present in individuals exhibiting dysmetabolism, suggesting that major alterations of the gut microbiome and metabolome might begin long before clinical onset of {IHD}. {W}e further categorized microbiome and metabolome signatures related to prodromal dysmetabolism, specific to {IHD} in general or to each of its three subtypes or related to escalation or de-escalation of {IHD}. {D}iscriminant analysis based on specific {IHD} microbiome and metabolome features could better differentiate individuals with {IHD} from healthy individuals or metabolically matched individuals as compared to the conventional risk markers, pointing to a pathophysiological relevance of these features.},
  keywords = {{EUROPE} ; {DANEMARK} ; {FRANCE} ; {ALLEMAGNE}},
  booktitle = {},
  journal = {{N}ature {M}edicine},
  volume = {28},
  numero = {},
  pages = {303--314 + 19 p.},
  ISSN = {1078-8956},
  year = {2022},
  DOI = {10.1038/s41591-022-01688-4},
  URL = {https://www.documentation.ird.fr/hor/fdi:010084326},
}